Trial Profile
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs ODM-208 (Primary) ; Dexamethasone; Fludrocortisone; Glucocorticoids; Midazolam
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Acronyms CYPIDES
- Sponsors Orion Pharma
- 27 Jan 2024 Results (at data cut-off17 July 2023 ) presented at the 2024 Genitourinary Cancers Symposium
- 26 Jan 2024 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.
- 26 Jan 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2024.